{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T12:22:30Z","timestamp":1795090950859,"version":"4.10.2"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,2]]},"DOI":"10.7759\/cureus.35701","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T14:52:46Z","timestamp":1677768766000},"source":"Crossref","is-referenced-by-count":2,"title":["Drug-Induced Reaction With Eosinophilia and Systemic Symptoms: A Review"],"prefix":"10.7759","author":[{"given":"Moteb","family":"Alotaibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjae.2019.11.001","article-title":"Drug reactions with eosinophilia and systemic symptoms","volume":"20","author":"Scrace B","year":"2020","unstructured":"Scrace B, Fityan A, Bigham C. Drug reactions with eosinophilia and systemic symptoms. BJA Educ. 2020, 20:65-71. 10.1016\/j.bjae.2019.11.001","journal-title":"BJA Educ"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s1085-5629(96)80038-1","article-title":"Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS)","volume":"15","author":"Bocquet H","year":"1996","unstructured":"Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg. 1996, 15:250-7. 10.1016\/s1085-5629(96)80038-1","journal-title":"Semin Cutan Med Surg"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s13671-021-00348-z","article-title":"Updates and Insights in the diagnosis and management of DRESS Syndrome","volume":"10","author":"Schunkert EM","year":"2021","unstructured":"Schunkert EM, Divito SJ. Updates and Insights in the diagnosis and management of DRESS Syndrome. Curr Dermatol Rep. 2021, 10:192-204. 10.1007\/s13671-021-00348-z","journal-title":"Curr Dermatol Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.08.013","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome identified in the electronic health record allergy module","volume":"7","author":"Wolfson AR","year":"2019","unstructured":"Wolfson AR, Zhou L, Li Y, Phadke NA, Chow OA, Blumenthal KG. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome identified in the electronic health record allergy module. J Allergy Clin Immunol Pract. 2019, 7:633-40. 10.1016\/j.jaip.2018.08.013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0318-7","article-title":"Cutaneous adverse effects of neurologic medications","volume":"30","author":"Bahrani E","year":"2016","unstructured":"Bahrani E, Nunneley CE, Hsu S, Kass JS. Cutaneous adverse effects of neurologic medications. CNS Drugs. 2016, 30:245-67. 10.1007\/s40263-016-0318-7","journal-title":"CNS Drugs"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22042147","article-title":"Current perspective regarding the immunopathogenesis of drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms (DIHS\/DRESS)","volume":"22","author":"Miyagawa F","year":"2021","unstructured":"Miyagawa F, Asada H. Current perspective regarding the immunopathogenesis of drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms (DIHS\/DRESS). Int J Mol Sci. 2021, 22:10.3390\/ijms22042147","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10050999","article-title":"Drug reaction with eosinophilia and systemic symptoms (DReSS)\/drug-induced hypersensitivity syndrome (DiHS)-readdressing the DReSS","volume":"10","author":"Stirton H","year":"2022","unstructured":"Stirton H, Shear NH, Dodiuk-Gad RP. Drug reaction with eosinophilia and systemic symptoms (DReSS)\/drug-induced hypersensitivity syndrome (DiHS)-readdressing the DReSS. Biomedicines. 2022, 10:10.3390\/biomedicines10050999","journal-title":"Biomedicines"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.02.004","article-title":"Drug-induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis","volume":"10","author":"Hama N","year":"2022","unstructured":"Hama N, Abe R, Gibson A, Phillips EJ. Drug-induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis. J Allergy Clin Immunol Pract. 2022, 10:1155-1167.e5. 10.1016\/j.jaip.2022.02.004","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2019.03.006","article-title":"Drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019","volume":"68","author":"Shiohara T","year":"2019","unstructured":"Shiohara T, Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019. Allergol Int. 2019, 68:301-8. 10.1016\/j.alit.2019.03.006","journal-title":"Allergol Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0733-7","article-title":"Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report","volume":"26","author":"Kim D","year":"2020","unstructured":"Kim D, Kobayashi T, Voisin B, et al.. Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report. Nat Med. 2020, 26:236-43. 10.1038\/s41591-019-0733-7","journal-title":"Nat Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/all.15283","article-title":"Targeting interleukin-5 with benralizumab: a novel treatment for drug rash with eosinophilia and systemic symptoms","volume":"77","author":"Maverakis E","year":"2022","unstructured":"Maverakis E, Ji-Xu A, Br\u00fcggen MC. Targeting interleukin-5 with benralizumab: a novel treatment for drug rash with eosinophilia and systemic symptoms. Allergy. 2022, 77:2287-9. 10.1111\/all.15283","journal-title":"Allergy"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.02.1130","article-title":"Liver injury in patients with DRESS: a clinical study of 72 cases","volume":"72","author":"Lin IC","year":"2015","unstructured":"Lin IC, Yang HC, Strong C, Yang CW, Cho YT, Chen KL, Chu CY. Liver injury in patients with DRESS: a clinical study of 72 cases. J Am Acad Dermatol. 2015, 72:984-91. 10.1016\/j.jaad.2015.02.1130","journal-title":"J Am Acad Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun SH","year":"2013","unstructured":"Kardaun SH, Sekula P, Valeyrie-Allanore L, et al.. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013, 169:1071-80. 10.1111\/bjd.12501","journal-title":"Br J Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.idoj_196_21","article-title":"RegiSCAR DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) Validation Scoring System and Japanese Consensus Group Criteria for Atypical Drug-Induced Hypersensitivity Syndrome (DiHS): a comparative analysis","volume":"13","author":"Sasidharanpillai S","year":"2022","unstructured":"Sasidharanpillai S, Ajithkumar K, Jishna P, Khader A, Anagha KV, Binitha MP, Chathoth AT. RegiSCAR DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) Validation Scoring System and Japanese Consensus Group Criteria for Atypical Drug-Induced Hypersensitivity Syndrome (DiHS): a comparative analysis. Indian Dermatol Online J. 2022, 13:40-5. 10.4103\/idoj.idoj_196_21","journal-title":"Indian Dermatol Online J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal GP","year":"2011","unstructured":"Aithal GP, Watkins PB, Andrade RJ, et al.. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011, 89:806-15. 10.1038\/clpt.2011.58","journal-title":"Clin Pharmacol Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.075","article-title":"Clinical, biochemical, and serologic predictors of drug reaction with eosinophilia and systemic symptoms syndrome: a prospective case-control study","volume":"85","author":"Choudhary R","year":"2021","unstructured":"Choudhary R, Vinay K, Srivastava N, et al.. Clinical, biochemical, and serologic predictors of drug reaction with eosinophilia and systemic symptoms syndrome: a prospective case-control study. J Am Acad Dermatol. 2021, 85:901-9. 10.1016\/j.jaad.2021.03.075","journal-title":"J Am Acad Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2016.06.003","article-title":"Serum TARC levels are strongly correlated with blood eosinophil count in patients with drug eruptions","volume":"66","author":"Komatsu-Fujii T","year":"2017","unstructured":"Komatsu-Fujii T, Kaneko S, Chinuki Y, Suyama Y, Ohta M, Niihara H, Morita E. Serum TARC levels are strongly correlated with blood eosinophil count in patients with drug eruptions. Allergol Int. 2017, 66:116-22. 10.1016\/j.alit.2016.06.003","journal-title":"Allergol Int"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.11.008","article-title":"Risk of progression to autoimmune disease in severe drug eruption: risk factors and the factor-guided stratification","volume":"142","author":"Mizukawa Y","year":"2022","unstructured":"Mizukawa Y, Aoyama Y, Takahashi H, Takahashi R, Shiohara T. Risk of progression to autoimmune disease in severe drug eruption: risk factors and the factor-guided stratification. J Invest Dermatol. 2022, 142:960-968.e9. 10.1016\/j.jid.2021.11.008","journal-title":"J Invest Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/all.15089","article-title":"Advances and highlights in biomarkers of allergic diseases","volume":"76","author":"Ogulur I","year":"2021","unstructured":"Ogulur I, Pat Y, Ardicli O, et al.. Advances and highlights in biomarkers of allergic diseases. Allergy. 2021, 76:3659-86. 10.1111\/all.15089","journal-title":"Allergy"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0480","article-title":"Spanish guidelines for diagnosis, management, treatment, and prevention of DRESS syndrome","volume":"30","author":"Caba\u00f1as R","year":"2020","unstructured":"Caba\u00f1as R, Ram\u00edrez E, Sendagorta E, et al.. Spanish guidelines for diagnosis, management, treatment, and prevention of DRESS syndrome. J Investig Allergol Clin Immunol. 2020, 30:229-53. 10.18176\/jiaci.0480","journal-title":"J Investig Allergol Clin Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14207","article-title":"Short course of cyclosporin A as a treatment option for drug-induced hypersensitivity syndrome: case reports and review of the published work","volume":"45","author":"Hashizume H","year":"2018","unstructured":"Hashizume H, Kageyama R, Kaneko Y. Short course of cyclosporin A as a treatment option for drug-induced hypersensitivity syndrome: case reports and review of the published work. J Dermatol. 2018, 45:e169-70. 10.1111\/1346-8138.14207","journal-title":"J Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0048","article-title":"Evaluation of cyclosporine for the treatment of DRESS syndrome","volume":"156","author":"Nguyen E","year":"2020","unstructured":"Nguyen E, Yanes D, Imadojemu S, Kroshinsky D. Evaluation of cyclosporine for the treatment of DRESS syndrome. JAMA Dermatol. 2020, 156:704-6. 10.1001\/jamadermatol.2020.0048","journal-title":"JAMA Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5123","article-title":"Erosive cheilitis as an early manifestation in DRESS syndrome","volume":"9","author":"Ben Salha W","year":"2021","unstructured":"Ben Salha W, Moussaoui E, Oualha L, Anoun J, Douki N. Erosive cheilitis as an early manifestation in DRESS syndrome. Clin Case Rep. 2021, 9:e05123. 10.1002\/ccr3.5123","journal-title":"Clin Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/137824-drug-induced-reaction-with-eosinophilia-and-systemic-symptoms-a-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T11:52:47Z","timestamp":1795089167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/137824-drug-induced-reaction-with-eosinophilia-and-systemic-symptoms-a-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.35701","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,2]]}}}